The Impact of the Epigenetic Cancer Drug Azacitidine on Host Immunity: The Role of Myelosuppression, Iron Overload and tp53 Mutations in a Zebrafish Model

The unsatisfactory real-world efficacy of the hypomethylating agent azacitidine in treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) has prompted us to investigate the hematological adverse events and host variables that may compromise the use of this epigenetic drug. Using t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shu-Ching, Wu, Ching-Tse, Wu, Dong-Yu, Chen, Caleb Gon-Shen, Chang, Kuo-Ming, Chang, Chien-Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770285/
https://www.ncbi.nlm.nih.gov/pubmed/31480804
http://dx.doi.org/10.3390/cancers11091294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770285/
https://www.ncbi.nlm.nih.gov/pubmed/31480804
http://dx.doi.org/10.3390/cancers11091294

Ejemplares similares